Intrauterine Devices Market Size, Share & Trends Analysis Report By Type (Hormonal IUD, Copper IUD), By Distribution Channel (Hospital, Gynecology Clinics), By Region, And Segment Forecasts, 2024 - 2030

Intrauterine Devices Market Size, Share & Trends Analysis Report By Type (Hormonal IUD, Copper IUD), By Distribution Channel (Hospital, Gynecology Clinics), By Region, And Segment Forecasts, 2024 - 2030

Intrauterine Devices Market Growth & Trends

The global intrauterine devices market is anticipated to reach USD 8.02 billion by 2030 and is projected to grow at a CAGR of 3.66% from 2024 to 2030, according to a new report by Grand View Research, Inc. There is a growing awareness of family planning and reproductive health, leading to higher rates of contraceptive usage globally. Government initiatives aiming to reduce unintended pregnancies have also contributed to the adoption of effective contraceptive methods, such as intrauterine devices (IUD). Technological advancements in IUD design, including the introduction of various hormonal and non-hormonal options, cater to diverse consumer preferences and improve user experience. Moreover, the trend towards long-acting reversible contraceptives (LARCs), which provide convenience and effectiveness without daily intervention, is gaining traction, particularly among younger demographics.

The government spending on contraceptives is growing rapidly, and this is expected to drive market growth over the forecast period. According to the Family Planning 2030 report, the U.S. accounted for USD 582.9 million (43%), followed by the Netherlands USD 217.4 million (16%), UK USD 174.7 million (13%), Sweden USD 121.3 million (9%) and Canada USD 88.3 million (7%) funding from the government for bilateral family planning in 2022.

Due to the highly consolidated market with major players, companies are focusing on significant investments in research and development, as well as adopting various strategies such as mergers and acquisitions and expanding their product pipelines. For instance, in November 2022, Medicines360 obtained FDA approval for the Liletta hormonal IUD for preventing pregnancy for up to 8 years. The approval was granted after evaluating additional efficacy and safety data from a phase 3 clinical trial involving 1,751 women in the U.S. and using Liletta 52 mg.

Intrauterine Devices Market Report Highlights

• Based on type, the hormonal IUDs segment led the market with the largest revenue share of 72.99% in 2023. This is attributed to the high pregnancy prevention efficacy, reduced menstrual bleeding, improved symptom management, and rising awareness, with healthcare providers recommending hormonal IUDs for their dual benefits and technological advancements attracting consumers
• Based on distribution channel, the hospital segment led the market with the largest revenue share of 54.44% in 2023. This is attributed to the high long-term benefits, comprehensive hospital family planning services, enhanced healthcare integration, expanding insurance coverage, and specialized staff boost demand and growth in this segment
• Asia Pacific dominated the market with the largest revenue share of 32.08% in 2023, which is attributed to rising acceptance of IUDs, supportive government policies, increased focus on women's healthcare, and a growing preference for long-acting reversible contraception
• In October 2022, Bayer AG extended the usage duration of its levonorgestrel (LNG) releasing IUD Mirena to up to eight years in Europe. This approval, based on the Mirena Extension Trial, confirms over 99% contraceptive efficacy from year six to eight

Please note The report will be delivered in 2-3 business days upon order notification.